Pyxis Oncology (PYXS)
(Delayed Data from NSDQ)
$3.43 USD
+0.07 (2.08%)
Updated Aug 15, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Pyxis Oncology, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 82 | 123 | 70 | 13 | 0 |
Income After Depreciation & Amortization | -82 | -123 | -70 | -13 | 0 |
Non-Operating Income | 8 | 3 | -6 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -74 | -121 | -76 | -13 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -74 | -121 | -76 | -13 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -74 | -121 | -76 | -13 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -85 | -123 | -69 | -12 | 0 |
Depreciation & Amortization (Cash Flow) | -3 | 1 | 1 | 0 | NA |
Income After Depreciation & Amortization | -82 | -123 | -70 | -13 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 39.91 | 33.03 | 8.49 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.85 | -3.65 | -8.95 | NA | NA |
Diluted Net EPS (GAAP) | -1.85 | -3.65 | -8.95 | NA | NA |
Fiscal Year end for Pyxis Oncology, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 16.15 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.48 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 15.67 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 21.28 | 17.77 | 25.36 | 18.12 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -5.61 | -17.77 | -25.36 | -18.12 |
Non-Operating Income | NA | 2.35 | 2.17 | 2.31 | 2.22 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -3.26 | -15.60 | -23.05 | -15.90 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -3.26 | -15.60 | -23.05 | -15.90 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3.26 | -15.60 | -23.05 | -15.90 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 51.29 | 47.26 | 41.33 | 38.39 |
Diluted EPS Before Non-Recurring Items | NA | -0.06 | -0.33 | -0.56 | -0.41 |
Diluted Net EPS (GAAP) | NA | -0.06 | -0.34 | -0.56 | -0.41 |